Alpha 2.0
Login Register
» Authors » J M Kirkwood

J M Kirkwood

Explore the profile of J M Kirkwood including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 170
Citations 3831
Followers 0
Related Specialties
Oncology
Allergy & Immunology
General Medicine
Top 10 Co-Authors
M S Ernstoff
S S Agarwala
D R Vlock
T L Whiteside
P H Duray
T F Logan
R L Barnhill
M B Atkins
L Titus-Ernstoff
R H Blum
Published In
J Clin Oncol
Cancer Res
Cancer
Semin Oncol
J Am Acad Dermatol
Affiliations
Soon will be listed here.
Recent Articles
1.
Interferon Alfa-2b Adjuvant Therapy of High-Risk Resected Cutaneous Melanoma: The Eastern Cooperative Oncology Group Trial EST 1684
Kirkwood J, Strawderman M, Ernstoff M, Smith T, Borden E, Blum R
J Clin Oncol . 2023 Jan; 41(3):425-435. PMID: 36649675
Purpose: Interferon alfa-2b (IFN alpha-2b) exhibits antitumor activity in metastatic melanoma and on this basis has been evaluated as an adjuvant therapy following surgery for deep primary (T4) or regionally...
2.
Reply to the letters to the editor 'Differential influence of vemurafenib and dabrafenib on patients' lymphocytes despite similar clinical efficacy in melanoma' by Schilling et al
Davar D, Choi T, Kirkwood J
Ann Oncol . 2020 Jul; 26(1):251-252. PMID: 32599685
No abstract available.
3.
Targeting the MAPK pathway in advanced BRAF wild-type melanoma
Massa R, Kirkwood J
Ann Oncol . 2019 Mar; 30(4):503-505. PMID: 30821319
No abstract available.
4.
Psychosocial impact of skin biopsies in the setting of melanoma screening: a cross-sectional survey
Matthews N, Risica P, Ferris L, Beatson M, Saul M, Geller A, et al.
Br J Dermatol . 2018 Sep; 180(3):664-665. PMID: 30183068
No abstract available.
5.
Transcriptional repression of IFNβ1 by ATF2 confers melanoma resistance to therapy
Lau E, Sedy J, Sander C, Shaw M, Feng Y, Scortegagna M, et al.
Oncogene . 2015 Mar; 34(46):5739-48. PMID: 25728676
The resistance of melanoma to current treatment modalities represents a major obstacle for durable therapeutic response, and thus the elucidation of mechanisms of resistance is urgently needed. The crucial functions...
6.
Reply to the letters to the editor 'Differential influence of vemurafenib and dabrafenib on patients' lymphocytes despite similar clinical efficacy in melanoma' by Schilling et al
Davar D, Choi T, Kirkwood J
Ann Oncol . 2014 Nov; 26(1):251-2. PMID: 25361986
No abstract available.
7.
Re: Differential influence of vemurafenib and dabrafenib on patients' lymphocytes despite similar clinical efficacy in melanoma
Diwakar D, Choi T, Tawbi T, Kirkwood J
Ann Oncol . 2014 Jun; 25(8):1670-1. PMID: 24890848
No abstract available.
8.
Safety and efficacy of decitabine in combination with temozolomide in metastatic melanoma: a phase I/II study and pharmacokinetic analysis
Tawbi H, Beumer J, Tarhini A, Moschos S, Buch S, Egorin M, et al.
Ann Oncol . 2012 Nov; 24(4):1112-9. PMID: 23172636
Background: Temozolomide (TMZ) is widely used for chemotherapy of metastatic melanoma. We hypothesized that epigenetic modulators will reverse chemotherapy resistance, and in this article, we report studies that sought to...
9.
Inhibition of DNA repair with MGMT pseudosubstrates: phase I study of lomeguatrib in combination with dacarbazine in patients with advanced melanoma and other solid tumours
Tawbi H, Villaruz L, Tarhini A, Moschos S, Sulecki M, Viverette F, et al.
Br J Cancer . 2011 Aug; 105(6):773-7. PMID: 21811257
Background: The DNA repair protein O6-methylguanine-DNA methyltransferase (MGMT) reverses the O6-methylguanine (O6-meG) lesion induced by dacarbazine. Depletion of MGMT can be achieved using O6-meG pseudosubstrates. Herein, we report the first...
10.
Melanoma: immunotherapeutic approaches
Agarwala S, Kirkwood J
BioDrugs . 2007 Nov; 12(3):193-208. PMID: 18031176
The incidence of melanoma in the US is rising at a rate second only to that of lung cancer in women. Early stage melanoma is curable, but once metastatic, it...